Jan. 31, 2026 — The Society of Thoracic Surgeons (STS) has elected Vinay Badhwar, MD, as its 62nd president during the organization's Annual Meeting in New Orleans. Dr. Badhwar will guide the more than 8,000-member organization through a rapidly evolving health care landscape with a focus on technical excellence, data-driven science, and measurable impact for patients worldwide.

Feb. 2, 2026 — GE HealthCare has announced that Allia Moveo has received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Marking, bringing next-level mobility and precision to the interventional suite.

Jan. 28, 2026 — Corify Care has announced a major development in cardiac electrophysiology with the publication of its proprietary Global Volumetric Mapping technology in Nature Communications Medicine. The publication marks the first system capable of mapping all four heart chambers at once, providing physicians with a complete, real-time view of arrhythmias that current solutions cannot deliver.

Jan. 28, 2026 — Imperative Care has announced the commercial launch and first patient cases of the new Zoom 4S Catheter — an advanced aspiration thrombectomy device representing the company’s latest innovation in ischemic stroke treatment.

Jan. 27. 2026 — Circle Cardiovascular Imaging Inc. has announced the release of cvi42 v6.4, the latest version of its post-processing software. This release reinforces Circle CVI’s commitment to providing a single, seamless platform that powers faster, more reproducible and efficient cardiac imaging processing.

Jan. 27, 2026 —  BURL Concepts, a private company developing a rapid, automated and affordable test for evaluating cerebral blood flow and detecting emboli, announced the first human uses of the FOQUS ultrasound system, powered by SONAS, for brain emboli detection in the Netherlands and UK.

Jan. 27, 2026 — Cytokinetics, Inc. has announced that Myqorzo (aficamten) is now available for prescription in 5 mg, 10 mg, 15 mg and 20 mg tablets in the U.S. Myqorzo was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now